The potential mechanisms involving the genesis and growth of androgen-independent prostate cancer include super-expression of the androgen receptor (AR), in an attempt to compensate for the low androgenic plasma levels and mutations of this specific receptor, which could determine resistance to anti-androgenic therapy. However, most advanced prostate tumors have no mutations or amplifications of the AR, suggesting a potential role of non-androgenic growth factors, including epidermal growth factor (EGF), transforming growth factor α, insulin-like growth factor (IGF-1) and fibroblast growth factor. More specifically, these factors, and their receptors like EGFR (HER-1) and HER-2/neu, through paracrine and autocrine mechanisms, may contribute to the proliferation and growth of prostate cancer. Free full text available at www.tumorionline.it
GronbergH.: Prostate cancer epidemiology. Lancet, 361: 859–864, 2003.
2.
RiesL.A.G., MelbertD., KrapchoM.: SEER Cancer Statistics Review, 1975–2005, National Cancer Institute.Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/ (accessed October 1, 2010) based on November 2007 SEER data submission, posted to the SEER web site, 2008.
3.
Brasil. Ministério da Saúde.Secretaria de Atenção à Saúde. Instituto Nacional de Câncer. Coordenação de Prevenção e Vigilância de Câncer. Estimativas 2008: Incidência de Câncer no Brasil. Rio de Janeiro: INCA, 2007.
Di LorenzoG., AutorinoR., De LaurentiisM., CindoloL., D'ArmientoM., BiancoA.R., De PlacidoS.: HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori, 90: 163–170, 2004.
6.
ShihC., PadhyL.C., MurrayM., WeinbergR.A.: Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature, 290: 261–264, 1981.
7.
DrebinJ.A., LinkV.C., SternD.F., WeinbergR.A., GreeneM.I.: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell, 41: 697–706, 1985.
8.
RieseD.J., SternD.F.: Specificity within the EGF family/ErbB receptor family signaling network. Bioessays, 20: 41–48, 1998.
9.
BusseD., DoughtyR.S., ArteagaC.L.: HER-2/neu (erbB-2) and the cell cycle. Seminar Oncol, 27: 3–8, 2000.
10.
BeerliR.R., WelsW., HynesN.E.: Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem, 269: 23936–23946, 1994.
11.
QianX., LeVeaC.M., FreemanJ.K.: Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: A mechanism of interreceptor kinase activation and transphosphorylation. Proc Natl Acad Sci USA, 91: 1500–1504, 1994.
12.
HynesN.E., SternD.F.: The biology of erbB-2/neu/HER-s and its role in cancer. Biochim Biophys Acta, 198: 165–184, 1994.
13.
MalumbresM., PellicerA.: RAS pathway to cell cycle control and transformation. Front Biosci, 3: 887–912, 1998.
di Sant'AgneseP.A.: Neuroendocrine differentiation in prostatic carcinoma. Prostate, 39: 135–148, 1999.
22.
VolekJ.S., KraemerW.J., BushJ.A., IncledonT., BoetesM.: Testosterone and cortisol in relationship to dietary nutrients and resistance exercise. J Appl Physiol, 82: 49–54, 1997.
23.
WeissbergerA.J., HoK.K.: Activation of the somatotropic axis by testosterone in adult males: evidence for the role of aromatization. J Clin Endocrinol Metab, 76: 1407–1412, 1993.
24.
WellsA.: Molecules in focus: EGFR receptor. Int J Biochem Cell Biol, 31: 637–643, 1999.
25.
KokontisJ.M., LiaoS.: Molecular action of androgen in the normal and neoplastic prostate. Vitam Horm, 55: 219–307, 1999.
26.
HoneymanT.W., GoodmanH.M., FrayJ.C.S.: The effects of growth hormone on blood pressure and renin secretion in hypophysectomized rats. Endocrinology, 112: 1613–1617, 1983.
27.
ByrneR.L., LeungH., NealD.E.: Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol, 77: 627–633, 1993.
28.
MellonK., ThompsonS., CharltonR.G., MarshC., RobinsonM., LaneD.P., HarrisA.L., HorneC.H., NealD.E.: p53, c-erbB2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol, 147: 496–499, 1992.
29.
GiriD.K., WadhwaN., UpadhayaS.N., TalwarG.P.: Expression of Neu/HER-2 oncoprotein in prostate tumors: an immunohistochemical study. Prostate, 23: 329–336, 1993.
30.
SadasivanR., MorganR., JenningsS., AustenfeldM., Van VeldhuizenP., StephensR., NobleM.: Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol, 150: 126–131, 1993.
31.
SolomonD.S., BrandtR., CiardielloF., NormannoN.: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol-Hematol, 19: 183–232, 1995.
32.
FossaA., LillebyW., FossaS.D., GaudernackG., TorlakovicG., BernerA.: Independent prognostic significance of HER-2 oncoprotein expression in pNo prostate cancer undergoing curative radiotherapy. Int J Cancer, 99: 100–105, 2002.
33.
SanchezK.M., SweeneyC.J., MassR., KochM.O., GearyW.A., BaldridgeL.A., ZhangS., EbleJ.N., ChengL.: Evaluation of HER-2/neu expression in prostatic adenocarcinoma. Cancer, 95: 1650–1655, 2002.
34.
SignorettiS., MontironiR., ManolaJ., AltimariA., TamC., BubleyG., BalkS., ThomasG., KaplanI., HlatkyL., HahnfeldtP., KantoffP., LodaM.: Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst, 92: 1918–1925, 2000.
35.
Di LorenzoG., TortoraG., D'ArmientoF., De RosaG., StaibanoS., AutorinoR., D'ArmientoM., De LaurentiisM., De PlacidoS., CatalanoG., BiancoA.R., CiardelloF.: Expression of epidermal growth factor (EGFR) correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res, 8: 3438–3444, 2002.
36.
CraftN., ShostakY., CareyM., SwayersC.L.: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase. Nat Med, 5: 280–285, 1999.
37.
GioeliD., MandellJ.W., PetroniG.R., FriersonH.F.Jr., WeberM.J.: Activation of mitogen-activated protein kinase associated with with prostate cancer progression. Cancer Res, 59: 279–284, 1999.
38.
YehS., Kuan-LinH., KangH.Y., ThinT.H., Fong LinM., ChangC.: From HER-2/neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA, 96: 5458–5463, 1999.
39.
Del PesoL., Gonzalez-GarciaM., PageC., HerreraR., NunezG.: Interleukin-3 induced phosphorylation of BAD through the protein kinase Akt. Science, 278: 687–689, 1997.
40.
LinJ., AdamR.M., SantiestevanE., FreemanM.R.: The phosphatidylinositol 3'kinase is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res, 59: 3891–3897, 1999.
TyagiA., AgarwalW., AgarwalC.: Grape seed extract inhibits EGF-induced and constitutively active mitogenic signalling but activates JNK in human prostate carcinoma DU145 cells: Possible role in antiproliferation and apoptosis. Oncogene, 22: 1302–1316, 2003.
43.
YeR.D.: Regulation of nuclear factor Kb activation by G protein-coupled receptors. J Leuk Biol, 70: 839–848, 2001.
